13,971 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Avanza Fonder AB

Avanza Fonder AB acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 13,971 shares of the medical research company’s stock, valued at approximately $2,745,000.

Other institutional investors also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA boosted its stake in IQVIA by 1.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 140,039 shares of the medical research company’s stock valued at $29,610,000 after acquiring an additional 2,576 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of IQVIA by 21.1% during the second quarter. Mercer Global Advisors Inc. ADV now owns 13,043 shares of the medical research company’s stock worth $2,746,000 after purchasing an additional 2,277 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its stake in IQVIA by 3.0% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 9,112 shares of the medical research company’s stock worth $1,927,000 after purchasing an additional 264 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in IQVIA by 10.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,847 shares of the medical research company’s stock valued at $3,347,000 after buying an additional 1,552 shares during the last quarter. Finally, Blair William & Co. IL raised its stake in IQVIA by 8.8% during the second quarter. Blair William & Co. IL now owns 4,072 shares of the medical research company’s stock valued at $861,000 after buying an additional 328 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV stock opened at $197.25 on Friday. The company has a 50-day simple moving average of $200.09 and a 200 day simple moving average of $221.19. The company has a market capitalization of $35.80 billion, a P/E ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IQV. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.